Featured Trial:
Head and Neck Cancer Treatment

Featured Trial:
Breast Cancer Treatment

Featured Trial:
Melanoma Prevention Study

Featured Trial:
Breast Cancer Recurrence

Featured Trial:
Bladder Cancer Treatment

Featured Trial:
Pancreas Cancer Treatment

Featured Trial:
Stomach Cancer Treatment

Clinical and Administrative Resources

Web Application Portal

Submit an Inquiry

Update My Roster Profile

Other Research Resources

Member Blog

Resources for Active Trials

Training Video Resource Library on YouTube

Mentoring Program

Group Meeting Presentations, Audit Tools, and User Groups

Specialty Presentation:
Integrating PROs in Trials

Specialty Presentation:
Implementation Science

Latest News

July 23, 2026

Categories

Press Releases

Press Release: Proactive support to quit tobacco use during cancer treatment doubles quit rates in a nationwide trial

July 15, 2026

Categories

Press Releases

Press Release: ECOG-ACRIN ENDURANCE trial findings published in the New England Journal of Medicine provide the first randomized evidence on the optimal duration of lenalidomide maintenance for patients with newly diagnosed multiple myeloma

July 9, 2026

Categories

News Stories

Podcast: ASCO Post includes updated STAMP (EA6174) Merkel cell carcinoma data in its ASCO26 highlights, applauding cooperative groups for their ability to study rare cancers

June 29, 2026

Categories

The June 2026 News from ECOG-ACRIN blog is now available

June 10, 2026

Categories

Press Releases

Press Release: Elsa Anagnostou, Jordan Berlin, and Olisaemeka Ogbue receive ECOG-ACRIN 2026 scientific leadership and mentorship awards

June 4, 2026

Categories

News Stories

A new exploratory analysis from STAMP (EA6174) on aggressive Merkel cell cancer draws attention at ASCO 2026

June 2, 2026

Categories

News Stories

EA5142, an ALCHEMIST trial, adds to the knowledge base about optimal timing of adjuvant immunotherapy in non-small cell lung cancer

June 2, 2026

Categories

News Stories

WATCH: Dr. Jamie Chaft discusses the results of ALCHEMIST EA5142, a randomized phase 3 study of nivolumab after surgery and adjuvant chemotherapy in non-small cell lung cancer

June 1, 2026

Categories

News Stories

JAMA publishes ALCHEMIST EA5142 results: Nivolumab does not further reduce the risk of recurrence in patients with resected non-small cell lung cancer

Posts

ECOG-ACRIN Cancer Research Group Follow 9,347 6,600

Biomarker-driven medical research involving adults who have or are at risk of developing cancer

ECOG-ACRIN Cancer Research Group @eaonc ·

23h 2080748862428320009

#FindingsFriday: New in @JCO_ASCO, the EAQ171CD trial found that a virtual, sustained tobacco treatment program nearly doubled #SmokingCessation rates among patients with #cancer receiving care in community oncology settings. More: #CancerResearch

Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial...

PURPOSEPersistent smoking among patients diagnosed with cancer is associated with adverse clinical outcomes, yet tobacco ...

bit.ly

Reply on Twitter 2080748862428320009 Retweet on Twitter 2080748862428320009 0 Like on Twitter 2080748862428320009 0 Twitter 2080748862428320009

ECOG-ACRIN Cancer Research Group @eaonc ·

24 Jul 2080669456150278216

Do you have #AcuteMyeloidLeukemia (#AML) and are age 60 or older? If so, you may be able to participate in this study of a potential new treatment. Learn more: https://bit.ly/mm1oa-ea02-study #leukemia #leusm

Reply on Twitter 2080669456150278216 Retweet on Twitter 2080669456150278216 0 Like on Twitter 2080669456150278216 0 Twitter 2080669456150278216

ECOG-ACRIN Cancer Research Group @eaonc ·

24 Jul 2080654392919814283

Do you have newly diagnosed #Glioblastoma? If so, you may be able to participate in this study of a new treatment approach. Learn more about EAF223/GABLE here: https://bit.ly/gable-trial

Reply on Twitter 2080654392919814283 Retweet on Twitter 2080654392919814283 0 Like on Twitter 2080654392919814283 0 Twitter 2080654392919814283

About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More

ECOG-ACRIN by the Numbers

Active Clinical Trials

1400

Participating Institutions

International Sites

21000

Individual Members

Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, we are a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).